Starling Oncology, Inc.: cashflow_investing
| Value | {"amount": -202000, "concept": "us-gaap:NetCashProvidedByUsedInInvestingActivities", "currency": "USD"} |
|---|---|
| Period | 2025-01-01 – 2025-03-31 |
| Status | current |
| Entity | Starling Oncology, Inc. |
Provenance
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
Retrieved: 2026-08-19T18:08:38.724184+02:00
Raw response sha256:
Also addressable by official identifiers:
Cite as: FACTANKER, https://factanker.com/fact/f37f430f-0511-4fb5-8caf-152db14c3ed6
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
0001628280-25-025507Retrieved: 2026-08-19T18:08:38.724184+02:00
Raw response sha256:
f7bde1a401b286c74a2fd824ee1df541…Also addressable by official identifiers:
https://factanker.com/fact/sec/cik-0001799191/cashflow-investing/2025-03-31 (CIK, metric, reporting date)Cite as: FACTANKER, https://factanker.com/fact/f37f430f-0511-4fb5-8caf-152db14c3ed6
History
- no predecessors — first report